Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer to Perform Proteomics Analysis in Alzheimer s Research Partnership

NEW YORK, April 15 - PerkinElmer said today that it has entered a research collaboration with the Rush Alzheimer's Disease Center and the Buck Institute for Age Research to identify protein and gene targets involved in the onset and progression of Alzheimer's disease.

 

The Rush Alzheimer's Disease Center will supply brain tissue samples from patients who agreed to detailed annual clinical evaluations and brain donation at the time of death. The Buck Institute will perform genomic analysis on the tissue and PerkinElmer will perform proteomic studies to identify differentially expressed proteins in Alzheimer's and normal human brain tissue.

 

PerkinElmer and the Buck Institute said they would release their findings in a paper to be submitted later this year.

 

The proteomic analysis will be performed in PerkinElmer's Boston facility, and will involve up to 30 scientists led by Mary Lopez, director of biochemistry at PerkinElmer Life and Analytical Sciences.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.